Air Optix Extended Wear Contact Lenses
Launched by ALCON RESEARCH · May 24, 2023
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a non-interventional/observational study designed as a retrospective chart review. Study sites will identify charts within their existing databases in a fair and consistent manner, e.g., reviewing all eligible charts in reverse chronological order by year of baseline visit. Subjects/charts meeting the eligibility criteria will be enrolled in the study. The data collection period is defined as any approximately 1-year to 3-year timeframe since the respective lens brand was prescribed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Manifest refraction cylinder less than or equal to 0.75 diopter (D) in each eye at baseline (sphere wearers only);
- • Best corrected visual acuity (BCVA) of 20/25 Snellen or better in each eye at baseline;
- • Must have worn or be wearing Air Optix Aqua Sphere, Air Optix plus HydraGlyde Sphere, Air Optix plus HydraGlyde Toric, Biofinity Sphere or Biofinity Toric for at least 3 years in an extended wear modality, as determined by the Investigator;
- • Other protocol-defined inclusion criteria may apply.
- Exclusion Criteria:
- • Any recurrent history or active anterior segment infection, inflammation or abnormality contraindicating regular contact lens wear at baseline;
- • Use of systemic or ocular medications contraindicating regular contact lens wear at baseline and/or during the period of the retrospective chart collection;
- • Slit lamp findings, including signs of pathological dry eye, that would contraindicate regular contact lens wear;
- • Other protocol-defined exclusion criteria may apply.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Medina, Minnesota, United States
Orlando, Florida, United States
Saint Louis, Missouri, United States
Salt Lake City, Utah, United States
Patients applied
Trial Officials
Clinical Trial Lead, Vision Care
Study Director
Alcon Research, LLC
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported